No Data
No Data
Haichen Pharmaceutical (300584.SZ): APIs for some products are actively exploring new processes, including using biofermentation to replace traditional chemical synthesis processes
Gelonghui May 9 丨 Some investors asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does the company have synthetic biotechnology-related technology reserves?” The company replied that the APIs for some of the company's products are actively exploring new processes, including using biological fermentation to replace traditional chemical synthesis processes to further reduce production costs and increase profit margins.
Haichen Pharmaceutical (300584.SZ) announced its 2023 annual results, with net profit of 363.15,600 yuan, an increase of 11.92% year-on-year
According to Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 518 million yuan, a year-on-year decrease of 1.64%; net profit attributable to shareholders of listed companies was 363.15,600 yuan, an increase of 11.92% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 369.653 million yuan, an increase of 17.51% over the previous year; the company plans to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.
Express News | Haichen Pharmaceutical: Liu Xiaoquan plans to reduce its shareholding by no more than 0.90225%
Liu Xiaoquan, the main shareholder of Haichen Pharmaceutical (300584.SZ), reduced its shares by 1%
Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the shareholder holding more than 5% of the company's shares, reduced its holdings by 1.2 million shares, accounting for 1.00% of the total share capital.
Haichen Pharmaceutical (300584.SZ): Products suitable for mycoplasma pneumonia are mainly injectable azithromycin
Gelonghui March 6 丨 An investor asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does your company have drugs for mycoplasma pneumonia?” The company replied that the company's products for mycoplasma pneumonia are mainly injectable azithromycin.
Haichen Pharmaceutical (300584.SZ): The main products are injectable landilol hydrochloride, torasemide for injections, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company
Gelonghui March 4 | Haichen Pharmaceutical (300584.SZ) said on the investor interactive platform that the company's main products, such as injectable landilol hydrochloride, injectable torasemide, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company. Among them, injectable landiolol hydrochloride is the exclusive first imitation in China. At the end of 2023, it once again entered the national medical insurance catalogue with a simple contract renewal method; rivaroxaban tablets and injectable tigecycline were selected for centralized drug procurement nationwide. Pharmaceutical R&D innovation has the characteristics of difficulty, long cycle time, and high investment. In the future, the company will integrate clinical needs, its own R&D capabilities, and market conditions
No Data